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Background
There is a need in modern pharmacology for a representa-
tive animal model which should accurately mimic sporadic
Alzheimer’s disease (sAD), the prevailing type of dementia
in humans, and thus could be suitable for novel drug test-
ing. Rats treated intracerebroventricularly with the betacy-
totoxic agent streptozotocin (STZ-icv), have been
proposed recently as a non-transgenic sAD model which
demonstrates AD-like pathology features at cognitive, neu-
rochemical and structural level. In addition to the cogni-
tive deficits, pathological accumulation of amyloid b (Ab)
peptide is one of the neuropathological hallmarks of sAD,
and a growing body of evidence suggests the involvement
of insulin degrading enzyme (IDE), responsible for Ab
degradation, in sAD pathophysiology. We have explored
the time course of cognitive deficits and hippocampal
(HPC) IDE expression in the STZ-icv rat model of sAD,
and the therapeutic potential of the novel multifunctional
iron-chelating drug M30 to improve these deficits.
Methods
Adult Male Wistar rats were injected bilaterally icv with
STZ (0.3, 1 and 3 mg/kg) or vehicle and sacrificed one
week, or one, three, six and nine months after the treat-
ment. Two groups of STZ-icv (3 mg/kg)-injected rats were
additionally subjected to an 11-week oral M30 treatment
(2 and 10 mg/kg, 3x per week) beginning 10 days after the
STZ-icv treatment. Cognitive deficits were measured by
the Morris water maze swimming test (MWM) and the
passive avoidance test (PA). IDE protein expression in
HPC was measured by SDS-PAGE electrophoresis/immu-
noblotting. Data were analysed by the Kruskal-Wallis and
the Mann-Whitney U test (p < 0.05).
Results
STZ-icv rats exhibited significant dose- and time-depen-
dent cognitive deficits in the PA test (40–90%), while IDE
protein expression was found to be decreased not earlier
than one month after the STZ-icv administration (−56%),
persisting decreased untill six months (−26%). Treatment
with the high M30 dose improved STZ-icv-induced cogni-
tive deficits, observed as a decreased number of mistakes
in the MWM test (−60%) and increased latency time in
the PA test (+300%). Treatment with both M30 doses sig-
nificantly increased IDE protein expression in comparison
with the STZ-icv treatment alone (low dose +19%, high
dose +37%).
Conclusions
The STZ-icv rat model demonstrates long-term cognitive
deficits and decreased hippocampal IDE protein expres-
sion which tend to correlate mutually. Chronic M30
treatment, initiated after the development of cognitive
deficits, significantly improves the cognitive deficits as
well as decreases IDE protein expression in the STZ-icv
rat model of sAD, suggesting that multifunctional iron-
chelating drugs might have a therapeutic potential in
sAD treatment.
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